Somewhat Positive News Coverage Somewhat Unlikely to Affect Bristol-Myers Squibb (BMY) Stock Price

News articles about Bristol-Myers Squibb (NYSE:BMY) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.0963779074511 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news headlines that may have effected Accern Sentiment’s analysis:

Bristol-Myers Squibb opened at $54.47 on Thursday, Marketbeat Ratings reports. The company has a quick ratio of 1.39, a current ratio of 1.52 and a debt-to-equity ratio of 0.45. The firm has a market cap of $89.36 billion, a PE ratio of 18.10, a PEG ratio of 1.43 and a beta of 0.95. Bristol-Myers Squibb has a fifty-two week low of $49.96 and a fifty-two week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The business had revenue of $5.19 billion for the quarter, compared to analysts’ expectations of $5.25 billion. During the same quarter in the prior year, the firm posted $0.84 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. equities analysts forecast that Bristol-Myers Squibb will post 3.42 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 1st. Investors of record on Friday, July 6th will be issued a dividend of $0.40 per share. The ex-dividend date is Thursday, July 5th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.94%. Bristol-Myers Squibb’s dividend payout ratio is 53.16%.

A number of research firms have issued reports on BMY. Credit Suisse Group set a $58.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Tuesday, April 17th. BMO Capital Markets decreased their target price on Bristol-Myers Squibb from $51.00 to $47.00 and set an “underperform” rating on the stock in a research report on Wednesday, April 18th. Argus decreased their target price on Bristol-Myers Squibb from $75.00 to $66.43 and set a “buy” rating on the stock in a research report on Wednesday, March 21st. JPMorgan Chase & Co. set a $75.00 target price on Bristol-Myers Squibb and gave the company an “overweight” rating in a research report on Tuesday, March 20th. Finally, William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, April 17th. Three equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have issued a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $62.84.

In other Bristol-Myers Squibb news, Director Dinesh C. Paliwal acquired 4,770 shares of the business’s stock in a transaction dated Monday, April 30th. The shares were purchased at an average cost of $52.40 per share, for a total transaction of $249,948.00. Following the transaction, the director now owns 8,027 shares in the company, valued at $420,614.80. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 0.12% of the stock is owned by company insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Insider Buying and Selling by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with's FREE daily email newsletter.

Leave a Reply